Market Overview

Gilead Sciences Just Received Orphan Drug Status For Liver Treatment

Gilead Sciences Just Received Orphan Drug Status For Liver Treatment
Related GILD
Verastem's CEO Talks DYNAMO Study, The Competitive Landscape And Pitch To Investors
Orphan Drugs Among 2015's Top 10 Best-Selling Medications
Incyte Poised To Outperform Biotech Industry On Strong Pipeline (Investor's Business Daily)

Gilead Sciences, Inc. (NASDAQ: GILD) obtained orphan drug status on Monday for its simtuzumab as a treatment for a rare disorder related to the liver.

The designation, which concerns its potential as a treatment for primary sclerosing cholangitis, may provide Gilead increased patent protection and lower regulatory hurdles.

The status is reserved for treatments of diseases that affect fewer than 200,000 people in the United States, or for drugs that aren't expected to recover development costs.

Liver transplant is the only current treatment for primary sclerosing cholangitis.

Gilead is also attempting to develop simtuzamab as a treatment for liver Fibrosis and nonalcoholic steatohepatitis.

Simtuzamab in September proved unsuccessful in a Phase II trial as a treatment for pancreatic cancer.

Shares of Gilead Sciences changed hands recently at $98.73, up 1.1 percent.

Image credit: Jeffrey Beall, Wikimedia

Posted-In: simtuzamabNews FDA Intraday Update Movers Best of Benzinga


Related Articles (GILD)

View Comments and Join the Discussion!